Regulation - Pharmaceutical, Halaven

Filter

Current filters:

PharmaceuticalHalaven

Popular Filters

Eisai files for new Halaven indication; gets orphan status for lenvatinib in EU

08-05-2013

Japanese drug major Eisai (TYO: 4523) has filed a Type II Variation application with the European Medicines…

EisaiEuropeHalavenlenvatinibOncologyPharmaceuticalRegulation

Eisai expands in South Africa, filing for approval of Halaven and Fycompa

30-01-2013

Japanese drug major Eisai (TYO: 4523) says it is expanding its operations into South Africa, with the…

EisaiFycompaHalavenMarkets & MarketingNeurologicalOncologyPharmaceuticalRegulationRest of the World

Eisai gets South Korean approval for breast cancer drug Halaven

04-09-2012

The South Korean sales subsidiary of Japanese drug major Eisai (TYO: 4523) has received approval from…

Asia-PacificEisaiHalavenOncologyPharmaceuticalRegulation

Zonegran Russian approval prompts Eisai's expansion in that market

28-06-2012

Eisai (TYO: 4523), a leading Japanese drugmaker, says it plans to expand its operations into Russia,…

EisaiEuropeFycompaHalavenMarkets & MarketingNeurologicalPharmaceuticalRegulationZonegran

Eisai breast cancer drug still viewed as not cost effective by NICE

03-04-2012

In a third rejection, the UK drug watchdog the National Institute for Health and clinical Excellence…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

Added benefit of Eisai’s Halaven not proven, says Germany’s IQWiG

17-02-2012

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

UK’s NICE rejects Eisai’s Halaven for advanced breast cancer

17-11-2011

In a second negative from the UK’s National Institute for Health and Clinical Excellence, in final…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

Company Spotlight

ImmunoGen

ImmunoGen

Back to top